Edwall B, Arvidsson A, Lake-Bakaar D, Lanbeck-Vallén K, Yisak W
Department of Clinical Pharmacology, Astra Arcus, Södertälje, Sweden.
Drug Metab Dispos. 1993 Jan-Feb;21(1):171-7.
The pharmacokinetics of the main metabolites of cefcanel daloxate hydrochloride, a new oral cephalosporin diester prodrug, was investigated. Cefcanel is antimicrobially active. After oral administration of a single dose of [14C]cefcanel daloxate hydrochloride to 7 healthy male volunteers (group A), plasma concentrations (t1/2 approximately 1 hr) and excretion of radioactivity, cefcanel (Aer = 38.2 +/- 3.8%, t1/2 approximately 1 hr), mandelic acid glycine conjugate (Aer = 3.7 +/- 0.5%, t1/2 approximately 15 hr) and N-mandelyl-2-aminoethanol (Aer = 7.5 +/- 3.0%) were evaluated. The absolute oral bioavailability of cefcanel was approximately 40% after administration of cefcanel daloxate hydrochloride and the extent of urinary excretion of cefcanel, mandelic acid glycine conjugate, and N-mandelyl-2-aminoethanol after an equimolar intravenous administration of cefcanel, were determined in a separate, similar group of volunteers (N = 12, group B). Total plasma clearance of cefcanel was 179.1 +/- 22.4 ml/min/1.73 m2 after intravenous administration. Renal clearances of cefcanel were 173.9 +/- 95.6 (po, group B), 166.6 +/- 31.9 (i.v., group B), and 136.3 +/- 16.1 ml/min/1.73 m2 (po, group A). Cefcanel was almost completely (92.6 +/- 7.3%) excreted in the urine as unmetabolized drug after intravenous administration (group B). However, when cefcanel daloxate hydrochloride was administered orally, more than 30% of the total urinary excretion was due to metabolites other than cefcanel. A large proportion of these metabolites were formed at a late stage, in the absence of systemic cefcanel. It is probable that biotransformed materials, distinct from cefcanel, were formed in the gastrointestinal tract and slowly absorbed rather than being systemic products of metabolic degradation of cefcanel.(ABSTRACT TRUNCATED AT 250 WORDS)
对新型口服头孢菌素二酯前药盐酸头孢卡奈达酯的主要代谢产物的药代动力学进行了研究。头孢卡奈具有抗菌活性。给7名健康男性志愿者(A组)口服单剂量的[14C]盐酸头孢卡奈达酯后,评估了血浆浓度(t1/2约为1小时)以及放射性、头孢卡奈(Aer = 38.2 +/- 3.8%,t1/2约为1小时)、扁桃酸甘氨酸共轭物(Aer = 3.7 +/- 0.5%,t1/2约为15小时)和N-扁桃酰基-2-氨基乙醇(Aer = 7.5 +/- 3.0%)的排泄情况。在另一组相似的志愿者(N = 12,B组)中,静脉注射等摩尔量的头孢卡奈后,测定了盐酸头孢卡奈达酯给药后头孢卡奈的绝对口服生物利用度以及头孢卡奈、扁桃酸甘氨酸共轭物和N-扁桃酰基-2-氨基乙醇的尿排泄程度。静脉注射后头孢卡奈的总血浆清除率为179.1 +/- 22.4 ml/min/1.73 m2。B组口服给药后头孢卡奈的肾清除率为173.9 +/- 95.6,静脉注射后为166.6 +/- 31.9,A组口服给药后为136.3 +/- 16.1 ml/min/1.73 m2。静脉注射后(B组),头孢卡奈几乎完全(92.6 +/- 7.3%)以未代谢药物形式经尿液排泄。然而,口服盐酸头孢卡奈达酯时,总尿排泄量的30%以上归因于头孢卡奈以外的代谢产物。这些代谢产物中的很大一部分是在后期形成的,此时体内不存在头孢卡奈。很可能在胃肠道中形成了与头孢卡奈不同的生物转化物质,它们吸收缓慢,而不是头孢卡奈代谢降解的全身产物。(摘要截短至250字)